A citation-based method for searching scientific literature

Stephen M Ansell, Alexander M Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C Scott, Martin Gutierrez, Stephen J Schuster, Michael M Millenson, Deepika Cattry, Gordon J Freeman, Scott J Rodig, Bjoern Chapuy, Azra H Ligon, Lili Zhu, Joseph F Grosso, Su Young Kim, John M Timmerman, Margaret A Shipp, Philippe Armand. N Engl J Med 2015
Times Cited: 2253



Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe. Annu Rev Immunol 2008
Times Cited: 3131




List of shared articles



Times cited

Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC.
Olamide T Olaoba, Funmilayo C Ligali, Zaccheaus O Alabi, Amos O Akinyemi, Kehinde S Ayinde. Biochim Biophys Acta Rev Cancer 2021
1

PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements.
Rebeca Manso, Sandra Rodríguez-Perales, Raúl Torres-Ruiz, Carlos Santonja, Socorro-María Rodríguez-Pinilla. Leuk Lymphoma 2021
1

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
Ming Yi, Jing Zhang, Anping Li, Mengke Niu, Yongxiang Yan, Ying Jiao, Suxia Luo, Pengfei Zhou, Kongming Wu. J Hematol Oncol 2021
13

Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Julie B Mortensen, Ida Monrad, Marie B Enemark, Maja Ludvigsen, Peter Kamper, Mette Bjerre, Francesco d'Amore. Eur J Haematol 2021
1

Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy.
Chiara Cremolini, Emanuela Vitale, Raffaella Rastaldo, Claudia Giachino. Nanomaterials (Basel) 2021
0

Expression regulation and function of PD-1 and PD-L1 in T lymphoma cells.
Maria Y Liu, John D Klement, Candace J Langan, Jan van Riggelen, Kebin Liu. Cell Immunol 2021
0

Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy.
Mohammad-Javad Sanaei, Atieh Pourbagheri-Sigaroodi, Vahid Kaveh, Hassan Abolghasemi, Seyed H Ghaffari, Majid Momeny, Davood Bashash. Eur J Pharmacol 2021
1


Immune Checkpoints in Cancers: From Signaling to the Clinic.
Céline Pisibon, Amira Ouertani, Corine Bertolotto, Robert Ballotti, Yann Cheli. Cancers (Basel) 2021
0

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.
Gabriel K Griffin, Jason L Weirather, Margaretha G M Roemer, Mikel Lipschitz, Alyssa Kelley, Pei-Hsuan Chen, Daniel Gusenleitner, Erin Jeter, Christine Pak, Evisa Gjini,[...]. Blood 2021
6

Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors.
Yuan Wei, Xiao Xiao, Xiang-Ming Lao, Limin Zheng, Dong-Ming Kuang. Cell Mol Life Sci 2021
1

Immune checkpoint inhibition in COVID-19: risks and benefits.
Parmida Sadat Pezeshki, Nima Rezaei. Expert Opin Biol Ther 2021
5

PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS.
Maysaa Abdulla, Andrei Alexsson, Christer Sundström, Claes Ladenvall, Larry Mansouri, Cecilia Lindskog, Mattias Berglund, Lucia Cavelier, Gunilla Enblad, Peter Hollander,[...]. Acta Oncol 2021
0

Extracellular and nuclear PD-L1 in modulating cancer immunotherapy.
Wenjun Xiong, Yang Gao, Wenyi Wei, Jinfang Zhang. Trends Cancer 2021
0